104486-69-3

Usage

Uses

Used in Pharmaceutical Research:
ARG-PRO-LYS-PRO-GLN-GLN-PHE-PHE-PRO-LEU-MET-NH2 is used as a potential therapeutic agent for its specific biological activities and functions, which may be harnessed to target various diseases and conditions.
Used in Signaling Molecules:
In the biological signaling industry, ARG-PRO-LYS-PRO-GLN-GLN-PHE-PHE-PRO-LEU-MET-NH2 is used as a signaling molecule for its ability to interact with cellular receptors and initiate specific responses within the body.
Used in Hormone Development:
Within the field of endocrinology, this peptide is used as a component in the development of hormones, given its role in the body's regulatory mechanisms.
Used in Enzyme Formulation:
In the enzyme industry, ARG-PRO-LYS-PRO-GLN-GLN-PHE-PHE-PRO-LEU-MET-NH2 is used as a part of enzyme formulations, potentially contributing to catalytic activities and metabolic processes.
Each of these applications is based on the peptide's unique sequence and the biological roles that amino acids can play when combined in specific ways, offering a broad range of potential uses across different areas of medicine and biology.

InChI:InChI=1/C66H102N18O13S/c1-39(2)36-47(58(90)75-43(55(71)87)29-35-98-3)80-62(94)52-24-15-34-84(52)65(97)49(38-41-18-8-5-9-19-41)81-59(91)48(37-40-16-6-4-7-17-40)79-57(89)44(25-27-53(69)85)76-56(88)45(26-28-54(70)86)77-60(92)51-23-14-33-83(51)64(96)46(21-10-11-30-67)78-61(93)50-22-13-32-82(50)63(95)42(68)20-12-31-74-66(72)73/h4-9,16-19,39,42-52H,10-15,20-38,67-68H2,1-3H3,(H2,69,85)(H2,70,86)(H2,71,87)(H,75,90)(H,76,88)(H,77,92)(H,78,93)(H,79,89)(H,80,94)(H,81,91)(H4,72,73,74)/t42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-/m0/s1

Upstream product

• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 13139-15-6 N-tert-butoxycarbonyl-L-leucine 
• 2488-15-5 N-tert-butoxycarbonyl-L-methionine 
• 13734-34-4 N-tert-butoxycarbonyl-L-phenylalanine 

Relevant academic research and scientific papers

Tachykinin NK-1 receptor probed with constrained analogues of substance P

The action of rotameric probes introduced either in position 7 or 8 in the sequence of substance P (SP) was investigated, i.e. L-tetrahydroisoquinoleic acid (Tic) L-fluorenylglycine (Flg), L-diphenylalanine (Dip), the diastereoisomers of L-1-indanylglycine (Ing) and L-benz[f]indanylglycine (Bfi), the Z- and E-isomers of dehydrophenylalanine and dehydronaphthylananine (Δ(Z)Phe, Δ(E)Phe, Δ(Z)Nal, Δ(E)Nal) and L-o,o'-dimethylphenylalanine (Dmp). The aim of this study was the topographical characterization of the binding subsites of human NK-1 receptor expressed in CHO cells, especially the S7 and 8, subsites, corresponding to residues Phe7 and Phe8 of substance P. According to the binding potencies of these substituted-SP analogues, the S7 binding subsite is smaller than the S8 subsite: the S7 subsite accepts only one aromatic nucleus, while the S8 can accommodate three coplanar nuclei altogether. These findings are compatible with the idea that the S8 binding subsite may reside in the extracellular loops of the hNK-1 receptor. NK-1 agonists bind to human NK-1 receptor and activate the production of both inositol phosphates and cyclic AMP. As already quoted for septide, [pGlu6, Pro9]]SP(6-11), discrepancies are observed between affinity (K(i)) and activity (EC50) values for IPs production. While a weak correlation between K(i) and EC50 values for IPs production could be found (r=0.70), an excellent correlation could be demonstrated between their affinities (K(i)) and their potencies (EC50) for cAMP production (r=0.97). The high potency (EC50) observed for 'septide-like' molecules on PI hydrolysis, compared to their affinity is not an artefact related to the high level of NK-1 receptors expressed on CHO cells since a good correlation was found between EC50 values obtained for PI hydrolysis and those measured for spasmogenic activity in guinea pig ileum bioassay (r=0.94).